Lessons learned from the development of imatinib

Leukemia Research

Volumn 28, Issue SUPPL. 1, 2004, Pages

  Lydon, Nicholas B ^a   Druker, Brian J ^b,c  

^a STE 104 BME Box 25198 ^*  (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bcr Abl; CML; Drug design; Imatinib; STI 571; Tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PHOSPHOTRANSFERASE INHIBITOR;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPEREOSINOPHILIA; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TECHNOLOGY;

EID: 1342321786     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.10.002     Document Type: Article

References (83)

1. Druker B.J., Lydon N.B. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Invest. 105:2000;3-7.
2. Buchdunger E., Matter A., Druker B.J. Bcr-Abl inhibition as a modality of CML therapeutics. Biochim. Biophys. Acta. 1551:2001;M11-M18.
3. Mauro M.J., O'Dwyer M., Heinrich M.C., Druker B.J. STI571: a paradigm of new agents for cancer therapeutics. J. Clin. Oncol. 20:2002;325-334.
4. O'Dwyer M.E., Druker B.J. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Curr. Cancer Drug Targets. 1:2001;49-57.
5. Buchdunger E., Zimmermann J., Mett H.et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
6. Zimmermann J., Caravatti G., Mett H.et al. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch. Pharm. 329:1996;371-376.
7. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg. Med. Chem. Lett. 7:1997;187-192.
8. Druker B.J., Tamura S., Buchdunger E.et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nature Med. 2:1996;561-566.
9. Druker B.J., Talpaz M., Resta D.et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. New Engl. J. Med. 344:2001;1031-1037.
10. Druker B.J., Sawyers C.L., Kantarjian H.et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Engl. J. Med. 344:2001;1038-1042.
11. Kantarjian H., Sawyers C., Hochhaus A. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl. J. Med. 346:2002;645-652.
12. O'Brien S.G., Guilhot F., Larson R.A.et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl. J. Med. 348:2003;994-1004.
13. Sawyers C.L., Hochhaus A., Feldman E. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:2002;3530-3539.
14. Talpaz M., Silver R.T., Druker B.J.et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99:2002;1928-1937.
15. Buchdunger E., Zimmermann J., Mett H.et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 92:1995;2558-2562.
16. Zimmermann J., Buchdunger E., Mett H., Meyer T., Lydon N.B., Traxler P. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 6:1996;1221-1226.
17. Foulkes J.G., Chow M., Gorka C., Frackelton A.J., Baltimore D. Purification and characterization of a protein-tyrosine kinase encoded by the Abelson murine leukemia virus. J. Biol. Chem. 260:1985;8070-8077.
18. Lydon N.B., Adams B., Poschet J.F., Gutzwiller A., Matter A. An E. coli expression system for the rapid purification and characterization of a v-abl tyrosine protein kinase. Oncogene Res. 5:1990;161-173.
19. Lydon N.B., Gay B., Mett H.et al. Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase. Biochem. J. 287(Pt 3):1992;985-993.
20. McGlynn E., Liebetanz J., Reutener S.et al. Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus. J. Cell Biochem. 49:1992;239-250.
21. McGlynn E., Becker M., Mett H., Reutener S., Cozens R., Lydon N.B. Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors. Eur. J. Biochem. 207:1992;265-275.
22. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 241:1988;42-52.
23. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:2000;1938-1942.
24. Nagar B., Bornmann W.G., Pellicena P.et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243.
25. Taylor S.S., Radzio-Andzelm E., Cheng X., Ten Eyck L., Narayana N. Catalytic subunit of cyclic AMP-dependent protein kinase: structure and dynamics of the active site cleft. Pharmacol. Ther. 82:1999;133-141.
26. Cox S., Radzio-Andzelm E., Taylor S.S. Domain movements in protein kinases. Curr. Opin. Struct. Biol. 4:1994;893-901.
27. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell. 109:2002;275-282.
28. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96:2000;925-932.
29. Buchdunger E., Cioffi C.L., Law N. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:2000;139-145.
30. Deininger M.W., O'Brien S.G., Ford J.M., Druker B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 21:2003;1637-1647.
31. Deininger M.W., Goldman J.M., Lydon N., Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 90:1997;3691-3698.
32. Gambacorti-Passerini C., le Coutre P., Mologni L. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 23:1997;380-394.
33. Beran M., Cao X., Estrov Z.et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. 4:1998;1661-1672.
34. Carroll M., Ohno-Jones S., Tamura S.et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood. 90:1997;4947-4952.
35. le Coutre P., Mologni L., Cleris L.et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst. 91:1999;163-168.
36. Bishop J.M. Viral oncogenes. Cell. 42:1985;23-38.
37. Hunter T., Cooper J.A. Protein-tyrosine kinases. Ann. Rev. Biochem. 54:1985;897-930.
38. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
39. Witte O.N. Role of the BCR-ABL oncogene in human leukemia. Cancer Res. 53:1993;485-489.
40. Goldman J.M., Grosveld G., Baltimore D., Gale R.P. Chronic myelogenous leukemia - the unfolding saga. Leukemia. 4:1990;163-167.
41. Peng B., Hayes M., Racine-Poon A.et al. Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): a novel inhibitor of signal transduction. Proc. Am. Soc. Clin. Oncol. 20:2001;71a.
42. Hirota S., Isozaki K., Moriyama Y.et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:1998;577-580.
43. Rubin B.P., Singer S., Tsao C.et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121.
44. Edmonson J., Marks R., Buckner J., Mahoney M. Contrast of response to D-MAP + sargramostim between patients with advance malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc. ASCO. 18:1999;541a.
45. van Oosterom A.T., Judson I., Verweij J.et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 358:2001;1421-1423.
46. Demetri G.D., von Mehren M., Blanke C.D.et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl. J. Med. 347:2002;472-480.
47. Carroll M., Tomasson M.H., Barker G.F., Golub T.R., Gilliland D.G. The Tel platelet-derived growth factor beta receptor (PDGF-beta-R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF-beta-R kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. 93:1996;14845-14850.
48. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:1994;307-316.
49. Apperley J.F., Gardembas M., Melo J.V.et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. New Engl. J. Med. 347:2002;481-487.
50. Magnusson M.K., Meade K.E., Nakamura R., Barrett J., Dunbar C.E. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood. 100:2002;1088-1091.
51. Simon MP, Pedeutour F, Sirvent N, et al. Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nature Genetics 1997;15:95-8.
52. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001;61:5778-83.
53. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-6.
54. Rubin B.P., Schuetze S.M., Eary J.F.et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J. Clin. Oncol. 20:2002;3586-3591.
55. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 359:2002;1577-1878.
56. Cools J., DeAngelo D.J., Gotlib J.et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New Engl. J. Med. 348:2003;1201-1214.
57. Heinrich M.C., Corless C.L., Blanke C.D.et al. KIT mutational status predicts response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc. Am. Soc. Clin. Oncol. 21:2002;2a.
58. Heinrich M.C., Corless C.L., Duensing A.et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:2003;708-710.
59. Ekstrand A.J., Longo N., Hamid M.L.et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene. 9:1994;2313-2320.
60. Sharp P.A. RNA interference - 2001s. Genes Dev. 15:2001;485-490.
61. Lum L., Yao S., Mozer B.et al. Identification of Hedgehog pathway components by RNAi in Drosophila cultured cells. Science. 299:2003;2039-2045.
62. Ulrich R., Friend S.H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat. Rev. Drug Discov. 1:2002;84-88.
63. Bishop A.C., Ubersax J.A., Petsch D.T.et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature. 407:2000;395-401.
64. Moy F.J., Haraki K., Mobilio D.et al. MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. Anal. Chem. 73:2001;571-581.
65. Falb D., Jindal S. Chemical genomics: bridging the gap between the proteome and therapeutics. Curr. Opin. Drug Discov. Dev. 5:2002;532-539.
66. Weber L. The application of multi-component reactions in drug discovery. Curr. Med. Chem. 9:2002;2085-2093.
67. Tan D.S., Foley M.A., Shair M.D., Schreiber S.L. Stereoselective synthesis of over two million compounds having structural features both reminiscent of natural products and compatible with miniaturized cell-based assays. J. Am. Chem. Soc. 120:1998;8565-8566.
68. Schreiber S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science. 287:2000;1964-1969.
69. Wilson N.S., Roth G.P. Recent trends in microwave-assisted synthesis. Curr. Opin. Drug Discov. Dev. 5:2002;620-629.
70. Ley S.V., Baxendale I.R. New tools and concepts for modern organic synthesis. Nat. Rev. Drug Discov. 1:2002;573-586.
71. Toledo L.M., Lydon N.B., Elbaum D. The structure-based design of ATP-site directed protein kinase inhibitors. Curr. Med. Chem. 6:1999;775-805.
72. Rodrigues A.D. Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. Pharm. Res. 14:1997;1504-1510.
73. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44:2000;235-249.
74. Ficarro S.B., McCleland M.L., Stukenberg P.T.et al. Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat. Biotechnol. 20:2002;301-305.
75. McLachlin D.T., Chait B.T. Analysis of phosphorylated proteins and peptides by mass spectrometry. Curr. Opin. Chem. Biol. 5:2001;591-602.
76. Salomon A.R., Ficarro S.B., Brill L.M. Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 100:2003;443-448.
77. Marx J. Building better mouse models for studying cancer. Science. 299:2003;1972-1975.
78. Bardelli A., Parsons D.W., Silliman N.et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 300:2003;949.
79. Alizadeh A.A., Eisen M.B., Davis R.E.et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
80. Yeoh E.J., Ross M.E., Shurtleff S.A. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 1:2002;133-143.
81. Su A.I., Welsh J.B., Sapinoso L.M.et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 61:2001;7388-7393.
82. Ramaswamy S., Tamayo P., Rifkin R.et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl. Acad. Sci. U.S.A. 98:2001;15149-15154.
83. Hunter T. The proteins of oncogenes. Sci. Am. 251:1984;70-79.